Wegovy and Gout: Does Semaglutide Affect Uric Acid?

Why does losing weight quickly sometimes bring on a gout attack?

Gout flares during rapid weight loss are a well-recognised phenomenon, and they can catch people off guard. When fat cells break down quickly (whether through dietary restriction, bariatric surgery, or medicines that significantly reduce appetite) urate is released into the bloodstream faster than the kidneys can clear it. That transient spike in uric acid is enough to seed new crystals in a joint, or disturb existing deposits, triggering an acute attack.

Semaglutide, the active ingredient in Wegovy, does not directly raise uric acid as a pharmacological action. The mechanism here is the weight loss it produces, not the drug itself. STEP 1, the pivotal trial published in the New England Journal of Medicine, demonstrated average body-weight reductions of around 15% over 68 weeks at the 2.4 mg maintenance dose. Losses of that scale, particularly in the early months when titration is fastest and dietary intake drops most sharply, are precisely the window when urate can spike.

This does not mean people with gout should avoid Wegovy, far from it. It means the first few months deserve attention. Staying well hydrated, avoiding high-purine binges (organ meats, shellfish, alcohol), and telling your prescriber about any joint pain early gives you the best chance of moving through that window without incident. A question our prescribers hear most weeks is whether a new joint ache is a gout flare or something else entirely, and the honest answer is that only a clinical assessment can tell.

Does semaglutide make gout better or worse over time?

The long-term picture is generally more encouraging. Gout is tightly linked to obesity, insulin resistance and metabolic syndrome. Elevated uric acid and elevated BMI track together: fat tissue promotes urate synthesis, and excess weight impairs renal clearance of urate. As semaglutide-assisted weight loss is sustained over months and years, those underlying metabolic drivers ease. Studies of durable weight loss by other means (including bariatric surgery) consistently show falling serum urate over time, and there is every biological reason to expect the same trajectory with Wegovy.

There is also a separate piece of emerging evidence. GLP-1 receptor agonists appear to have a mild uricosuric effect (they nudge the kidney toward excreting more urate) independent of weight change. This is an active area of research rather than an established clinical fact, so it should be held lightly; the NHS patient information for semaglutide does not list gout either as a risk or as an intended benefit. What the evidence does support is that managing weight is one of the most effective long-term strategies for reducing gout frequency, and you can read more about how semaglutide works as a treatment to understand why it has become a clinically supported route to doing that.

The practical upshot: short-term vigilance, long-term optimism, but both filtered through a clinician who knows your uric acid history.

What should you tell your prescriber if you have a history of gout?

Be specific. It is not enough to mention gout in passing on a health questionnaire. Your prescriber benefits from knowing how frequent your flares have been, whether you are on allopurinol or febuxostat, and whether your uric acid has been checked recently. That context shapes several decisions: how cautiously to titrate your dose in the early weeks, whether to recommend urate monitoring alongside treatment, and what symptoms should prompt an early conversation rather than waiting for a scheduled review.

Allopurinol and Wegovy do not have a pharmacokinetic interaction (the medicines work through completely different pathways) but the clinical picture still needs to be held together rather than managed in separate silos. If you are considering Wegovy and want to understand what the full assessment involves, the consultation page sets out what our prescribers look at. You can also read more about whether Wegovy causes gout or explore the full Wegovy overview for a broader picture of the treatment.

People who experience a flare early in treatment sometimes assume Wegovy is simply wrong for them and stop. That may be premature. The flare risk is highest in the first few months; it does not persist at the same level as treatment continues and weight stabilises. Stopping and restarting can actually repeat that risk window. A conversation with your prescriber is nearly always more useful than a unilateral decision to pause.

Are there any practical steps that reduce flare risk on Wegovy?

Yes, and none of them are complicated. Hydration is first on the list. Semaglutide can reduce thirst alongside appetite, and reduced fluid intake slows renal urate clearance. Making a deliberate habit of drinking enough water matters more during active weight loss than at any other time. Aim for urine that is pale rather than dark; that is a more honest prompt than a daily millilitre target.

Diet still matters alongside treatment. Wegovy reduces how much you eat, but it does not change what you eat. Organ meats, oily shellfish, red meat in large quantities and alcohol (especially beer and spirits) all push urate up. The good news is that as appetite falls, many people naturally move toward lighter, less purine-dense foods without particular effort. That shift helps.

Exercise is worth mentioning too. Gentle, consistent activity supports both weight loss and metabolic health without the acute urate spikes that very intense exertion can sometimes cause in people who are susceptible. If you are thinking about how to stay active during treatment, our page on exercising on Wegovy covers the practical side of that. More detail on combining movement with semaglutide is also on the Wegovy and working out page.

Report any significant joint pain promptly. The Yellow Card scheme at yellowcard.mhra.gov.uk allows patients to flag suspected side effects directly to the MHRA, a useful channel if you experience something unexpected. And if you have broader questions about what treatment involves, our Wegovy page or a conversation via our support team is the place to start.